Abstract
The 90 kDa heat shock proteins (Hsp90) are proving to be an excellent target for the development of novel anticancer agents designed to selectively block the growth and proliferation of tumor cells. Since Hsp90 is a molecular chaperone and is responsible for folding numerous oncogenic proteins, its inhibition represents a novel approach toward the simultaneous disruption of multiple signaling cascades. This review summarizes recent literature implicating Hsp90 as a key facilitator for the maturation of proteins represented in all six hallmarks of cancer: 1) growth signal self-sufficiency, 2) anti-growth signal insensitivity, 3) evasion of apoptosis, 4) unlimited replicative potential, 5) metastasis and tissue invasion, and 6) sustained angiogenesis. Also described are recent advances towards the development of novel Hsp90 inhibitors via structure-based drug design that have contributed to the number of compounds undergoing clinical development.
Keywords: Hsp90, heat shock protein, cancer, inhibitor, molecular chaperone, protein folding, geldanamycin, radicicol
Current Cancer Drug Targets
Title: Hsp90: A Novel Target for the Disruption of Multiple Signaling Cascades
Volume: 7 Issue: 4
Author(s): Stephanie C. Bishop, Joseph A. Burlison and Brian S. J. Blagg
Affiliation:
Keywords: Hsp90, heat shock protein, cancer, inhibitor, molecular chaperone, protein folding, geldanamycin, radicicol
Abstract: The 90 kDa heat shock proteins (Hsp90) are proving to be an excellent target for the development of novel anticancer agents designed to selectively block the growth and proliferation of tumor cells. Since Hsp90 is a molecular chaperone and is responsible for folding numerous oncogenic proteins, its inhibition represents a novel approach toward the simultaneous disruption of multiple signaling cascades. This review summarizes recent literature implicating Hsp90 as a key facilitator for the maturation of proteins represented in all six hallmarks of cancer: 1) growth signal self-sufficiency, 2) anti-growth signal insensitivity, 3) evasion of apoptosis, 4) unlimited replicative potential, 5) metastasis and tissue invasion, and 6) sustained angiogenesis. Also described are recent advances towards the development of novel Hsp90 inhibitors via structure-based drug design that have contributed to the number of compounds undergoing clinical development.
Export Options
About this article
Cite this article as:
Bishop C. Stephanie, Burlison A. Joseph and J. Blagg S. Brian, Hsp90: A Novel Target for the Disruption of Multiple Signaling Cascades, Current Cancer Drug Targets 2007; 7 (4) . https://dx.doi.org/10.2174/156800907780809778
DOI https://dx.doi.org/10.2174/156800907780809778 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
In Silico Elucidation of the Plausible Inhibitory Potential of Withaferin A of Withania Somnifera Medicinal Herb Against Breast Cancer Targeting Estrogen Receptor
Current Pharmaceutical Biotechnology Improving the Efficacy of Plant Polyphenols
Anti-Cancer Agents in Medicinal Chemistry Studies of NVP-BEZ235 in Melanoma
Current Cancer Drug Targets Anticancer Activity and DNA Binding of 4-Alkylenediamines Modified Naphthalimide Derivatives
Letters in Drug Design & Discovery High Throughput Screening Technology and the Small Molecules Modulating Aging Related Signals
Combinatorial Chemistry & High Throughput Screening Engineered E. coli as Vehicles for Targeted Therapeutics
Current Gene Therapy Subject Index to Volume 4
Current Drug Metabolism The CCL2/CCR2 Axis in the Pathogenesis of HIV-1 Infection: A New Cellular Target for Therapy?
Current Drug Targets Poly(Ethylene Glycol) Amphiphilic Copolymer for Anticancer Drugs Delivery
Anti-Cancer Agents in Medicinal Chemistry Nanomedicine Advances in Topical Infective and Non-Infective Skin Diseases Therapy
Recent Patents on Anti-Infective Drug Discovery Dipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment
Current Drug Targets The Impact of Statin Therapy on the Survival of Patients with Gastrointestinal Cancer
Current Drug Targets MicroRNA Mediated Network and DNA Methylation in Colorectal Cancer
Protein & Peptide Letters Evidences and Opinions for Adjuvant Therapy in Pancreatic Cancer
Current Drug Targets Systems Biology Approaches and Metabolomics for Understanding Japanese Traditional Kampo Medicine
Current Pharmacogenomics and Personalized Medicine A Review of Techniques for Gene Therapy in Bone Healing
Current Stem Cell Research & Therapy Development of Curcumin-Loaded Solid Lipid Nanoparticles Utilizing Glyceryl Monostearate as Single Lipid Using QbD Approach: Characterization and Evaluation of Anticancer Activity Against Human Breast Cancer Cell Line
Current Drug Delivery Medicinal Chemistry Perspective of Fused Isoxazole Derivatives
Current Topics in Medicinal Chemistry Crocetin as an Active Secondary Metabolite of Saffron Stigma and Anticancer Effects
Current Cancer Therapy Reviews Molecular Mechanism of Deguelin in Anti-tumor Effect
Current Pharmaceutical Analysis